Skip to content
Screener

Pelthos Therapeutics PTHS Q2 2026 earnings

Reported August 13, 2026 · Before market open

Revenue$15.6MBeat by $430.7K
EPS-$6.62Miss by $3.80
Revenue estimate$15.2M
EPS estimate-$2.82
“The growing adoption of Zelsuvmi and an increasing number of prescriptions written contributed significantly to our strong performance in the second quarter. We expect further growth for Zelsuvmi, with over 4,200 units dispensed in July and total units dispensed since the launch surpassing a significant milestone of 30,000. We believe that our continued commercial success, combined with the Horizon facility, and potential access to additional funds subject to the lender's discretion, will provide us with the capital and flexibility necessary to advance our business plan. This includes the planned commercialization of Xepi® in the first quarter of 2027 and Xeglyze® in the third quarter of 2027.”
Convertible Preferred Stock

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$18.0M
EPS estimate-$2.90

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$102.53M+42.1%
Enterprise value$100.2M—
P/S3.7×—

FAQ

When did Pelthos Therapeutics report Q2 2026 earnings?
Pelthos Therapeutics (PTHS) reported Q2 2026 earnings on August 13, 2026 before market open.
What were Pelthos Therapeutics's Q2 2026 revenue and EPS?
Pelthos Therapeutics reported revenue of $15.6M and eps of $-6.62 for Q2 2026.
Did Pelthos Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $15.2M by $430.7K. EPS missed the consensus estimate of $-2.82 by $3.80.
How did Pelthos Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 23.0% from $-5.38.
Where can I find Pelthos Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001919246-26-000110) and the 10-Q/A periodic report (0001919246-26-000111) directly on SEC EDGAR. The filing index links above go to sec.gov.